Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
2nd June 2026 Uncategorised 0A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing that after 52 weeks it can normalize a key marker of disease progression for those with the liver disorder primary biliary cholangitis.
More: Gilead's Livdelzi scores in rare liver disease trial, portending use in broader patient population
Source: fierce